Therapeutic response and survival time of immunobiologicals in patients with moderate to severe psoriasis

An Bras Dermatol. 2022 Jan-Feb;97(1):112-115. doi: 10.1016/j.abd.2021.03.008. Epub 2021 Nov 20.

Authors

Cynthia Cristina Ferreira Mota¹, Ricardo Romiti², Marcelo Arnone², Andre Luís da Silva Hirayama², Maria Denise Fonseca Takahashi²

Affiliations

¹ Specialty Outpatient Clinic, Prefeitura Municipal de Santos, Santos, SP, Brazil; Psoriasis Outpatient Clinic, Prefeitura Municipal de Santos, Santos, SP, Brazil. Electronic address: cynthiamota@santos.sp.gov.br.
² Psoriasis Outpatient Clinic, Hospital das Clínicas da Universidade de São Paulo, São Paulo, SP, Brazil.

No abstract available

MeSH terms

Etanercept / therapeutic use
Humans
Hyperplasia
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Etanercept